Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Liver Cirrhosis

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Liver Cirrhosis in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Xiao, J1
Jin, C1
Liu, Z1
Guo, S1
Zhang, X1
Zhou, X1
Wu, X1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Liver Cirrhosis

ArticleYear
The design, synthesis, and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents.
    Organic & biomolecular chemistry, 2015, Jul-14, Volume: 13, Issue:26

    Topics: Actins; Apoptosis; Caspase 3; Cell Line; Cell Survival; Chemistry Techniques, Synthetic; Drug Design

2015